



HAL
open science

Inhaled antibodies: formulations require specific development to overcome instability due to nebulization

Alexie Mayor, Béatrice Thibert, Sylvain Huille, Renaud Respaud, Héroïse Audat, Nathalie Heuzé-Vourc'h

► To cite this version:

Alexie Mayor, Béatrice Thibert, Sylvain Huille, Renaud Respaud, Héroïse Audat, et al.. Inhaled antibodies: formulations require specific development to overcome instability due to nebulization. *Drug Delivery and Translational Research*, 2021, 11 (4), pp.1625-1633. 10.1007/s13346-021-00967-w . hal-03687135

HAL Id: hal-03687135

<https://univ-tours.hal.science/hal-03687135>

Submitted on 3 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Inhaled antibodies: formulations require specific development to overcome instability due to nebulization
2 Alexie Mayor^{1,2,3}, Béatrice Thibert³, Sylvain Huille³, Renaud Respaud, Héroïse Audat^{3,#}, Nathalie Heuzé-
3 Vourc'h^{1,2,*,#}

4

5 1 INSERM, Research Center for Respiratory Diseases, U1100, Tours, France

6 2 University of Tours, Tours, France

7 3 Sanofi, Formulation and Process Development, Impasse des Ateliers, 94400 Vitry-sur-Seine, France.

8

9 * Corresponding author at: INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, Université François
10 Rabelais de Tours, 10 Boulevard Tonnellé, F-37032 Tours, France. E-mail address: nathalie.vourch@med.univ-
11 tours.fr (N. Heuzé-Vourc'h).

12 # contributed equally to the design and supervision of this work

13

14 ORCID number:

15 NHV, 0000-0003-4929-5068

16 AM, 0000-0001-5700-6196

17

18 **Abstract (150-250 words): 197 words**

19

20 Respiratory infections are life-threatening and therapeutic antibodies (Ab) have a tremendous opportunity to
21 benefit to patients with pneumonia due to multidrug resistance bacteria or emergent virus, before a vaccine is
22 manufactured. In respiratory infections, inhalation of anti-infectious Ab may be more relevant than intravenous
23 (IV) injection – the standard route– to target the site of infection and improve Ab therapeutic index. One major
24 challenge associated to Ab inhalation is to prevent protein instability during the aerosolization process. Ab drug
25 development for IV injection aims to design a high-quality product, stable to different environment stress. In this
26 study, we evaluated the suitability of Ab formulations developed for IV injection to be extended for inhalation
27 delivery. We studied the aerosol characteristics and the aggregation profile of three Ab formulations developed
28 for IV injection after nebulization, with two mesh-nebulizers. Although the formulations for IV injection were
29 compatible with mesh-nebulization and deposition into the respiratory tract, the Ab were more unstable during
30 nebulization than exposition to a vigorous shaking. Overall, our findings indicate that Ab formulations developed
31 for IV delivery may not easily be repurposed for inhalation delivery and point to the requirement of a specific
32 formulation development for inhaled Ab.

33

34 **Keywords (4-6):** monoclonal antibody, inhalation, respiratory tract infections, formulation development, mesh-
35 nebulization

36

37 **Declarations**

38 - Funding:

39 This work was supported by the French National Research Agency as part of the “Investissements d’Avenir”
40 program (LabEx MAbImprove, ANR-10-LABX-53-01) and SANOFI. AM was funded by a CIFRE thesis
41 partnership between the CEPR-Inserm U1100 and Sanofi.

42 - Conflict of interests/competing interests

43 NHV is co-founder and scientific expert for Cynbiose Respiratory. In the past 3 years, she received consultancy
44 fees from Argenx, Eli Lilly and research support from Signia Therapeutics, Sanofi and Aerogen Ltd.

45 - Ethics approval: not applicable

46 - Consent to participate: not applicable

47 - Availability of data and material:

48 The datasets generated during and/or analyzed during the current study are available from the corresponding author
49 on reasonable request.

50 - laboratory notebooks filled and signed by the co-workers

51 - Code availability: not applicable

52 - Author’s contributions:


53 A.M. participated in the design and implemented all the experiments,

54 B.T. implemented some experiments

55 N.HV, R.R, H.A & S.H participated in the design and supervision of research

56 All authors contributed to the manuscript.

57



60 Introduction

61 Acute respiratory infections remain a major health issue, as recently highlighted by the SARS-CoV2 pandemic.
62 Overall, acute respiratory infections are the world's fourth leading cause of death in human of all ages and the first
63 one among children under 5 year-old [1,2]. Although treatments, such as vaccines and antibiotics have been
64 developed, respiratory infections are not under control, mainly because of increasing occurrence of antibiotic-
65 resistant bacteria and emerging viral pathogens. For instance, SARS-CoV2 infection, which can lead to severe
66 pneumonia and respiratory distress syndrome, has already caused more than 2,500,000 deaths around the world,
67 as of March 2021 [3]. Facing this major threat of public health, innovative anti-infective approaches are urgently
68 needed. Among them, therapeutic antibodies (Ab) is a growing class of anti-infective agents, with 3 monoclonal
69 Ab marketed and indicated in respiratory infections, and several molecules targeting respiratory pathogens –
70 including 90 anti-SARS-CoV2 Abs - in development [4–6]. Anti-infective Ab are mostly full-length IgG, acting
71 directly by neutralizing the pathogens and/or stimulating immune responses. As exemplified by the SARS-CoV2
72 pandemic, therapeutic Ab, that do not target the pathogens and are already approved in non-communicable
73 diseases, may also be relevant to prevent respiratory infection-mediated uncontrolled inflammation or abnormal
74 coagulation.

75 Presently, most anti-infective Ab are administered intravenously (IV) [4], but the inhalation route may be more
76 appropriate to improve Ab therapeutic index in respiratory infections, matching the delivery route with the
77 pathogen one, limiting systemic passage and associated risk of systemic toxicity, along with possibly reducing the
78 dose to administer. Inhalation is the mainstay route for drug delivery to treat pulmonary diseases, such as asthma
79 and chronic obstructive pulmonary diseases (COPD) [7,8]. Inhalation consists in delivering a drug as an aerosol -
80 a suspension of 1 to 5 μm -solid particles or -liquid droplets in a gas- directly into the respiratory tract. Most inhaled
81 drugs are small-molecules, like corticosteroids, beta-sympathomimetics, muscarinic antagonists, and antibiotics.
82 The inhalation route remains underexploited for biotherapeutics, with only one protein therapeutics approved so
83 far, Pulmozyme® [9]. Despite inhalation of interferon- β (SNG001, Synairgen) recently achieved positive results
84 in phase 2 clinical trial in hospitalized COVID-19 patients (NCT04385095) [10], the inhalation route is often
85 dismissed/neglected for protein therapeutics because of the lack of supportive clinical data demonstrating its
86 benefit and the challenges associated to inhaled protein development [11–13]. Better understanding the behaviour
87 of inhaled Ab during aerosolization and after deposition into the respiratory tract is critical to support development
88 of appropriate and successful anti-infective Ab products.

89 Pharmaceutical development aims to design a high-quality product and its associated manufacturing process
90 ensuring an efficacious and safe treatment along the life of the product [14]. The formulation scientists play a
91 critical role to produce Ab, with an adequate formulation to ensure shelf life stability and appropriate quality.
92 During formulation development, quality by design principles and ICH guidelines are applied, in particular for
93 biotherapeutics ICH Q1A(R2), Q6B and Q8 (R2) [15–17]. Usually, parenteral (IV or subcutaneous) Ab
94 formulations are developed for storage at $5\text{ }^{\circ}\text{C} \pm 3\text{ }^{\circ}\text{C}$ for at least two years and should protect the Ab against
95 stress, such as temperature changes, light exposure or shearing associated to shaking during transport and
96 administration to patients. For inhalation, most protein therapeutics in clinical trial are developed as a liquid
97 aerosol, intended to be delivered by nebulization – transforming solutions in micron droplets [9]. During
98 nebulization, proteins are subjected to multiple stress, like temperature rise, exposure to interfaces (liquid-solid or
99 liquid-gas), ultrasound and mechanical shearing [9,18,19]. Ultimately, nebulization can result in Ab aggregation,

100 which may be associated with impaired biological activity and/or unexpected immune responses. As shown in
101 recent published studies, mesh-nebulization is suitable to administer efficiently high dose of proteins into the lungs
102 and limit Ab aggregation [9,18,19].

103 Herein, we hypothesized that liquid formulations developed for intravenous delivery may be appropriate for
104 inhalation delivery, which can facilitate a quick product development to assess the interest of the inhaled route for
105 anti-infectious Ab or repurpose easily relevant IgG molecules during health crisis. In this study, we evaluated the
106 stability of three pharmaceutical Ab formulations during mesh-nebulization in comparison to a vigorous
107 mechanical shaking stress.

108

109 **Material and Methods**

110 *Antibodies*

111 Three Ab were supplied by Sanofi in their pharmaceutical formulations, compatible for intravenous (IV)
112 administration. They are all full-length IgG1. mAb1 was formulated at 20 mg/mL in histidine buffer at pH 6.0,
113 mAb2 was formulated at 10 mg/mL in histidine buffer at pH 5.8 and mAb3 was formulated at 30 mg/mL in
114 phosphate buffer at pH 6.0. The formulation had the following characteristics: mAb1 2Cp (20°C) and 360
115 mOsm/kg, mAb2 1.3Cp (20°C) and 307 mOsm/kg and mAb3 2.4Cp (20°C) and 306 mOSm/kg. All formulations
116 contained polysorbate 80. Before nebulization, all Ab were filtered to eliminate residual particles (0.22 µm PES
117 syringe filter, Sartorius).

118

119 *Antibody nebulization and aerosol collection*

120 Two types of vibrating-mesh nebulizers, which are known to limit Ab instability, were used in this study [20]. The
121 Device 1 was a commercial vibrating-mesh nebulizer and the Device 2 was a customized vibrating-mesh nebulizer.
122 Between each nebulization, nebulizers were washed in a bath of hot water (45-55°C) with a detergent product
123 compatible for non-invasive medical devices (Surfanios premium) and rinsed with purified water. Then, 2 mL of
124 purified water were nebulized to remove residual particles and detergent. For Ab nebulization, 2 mL of Ab
125 solutions were introduced in the nebulizer reservoir. The aerosols were collected in a 15-mL sterile conical tube
126 (Corning Life Sciences) by condensation. **As recently described, the collection efficiency is approximately 60%**
127 **[21].** Each Ab was nebulized in triplicate on each device. The nebulized and collected Ab was immediately
128 analysed for aggregation.

129 The performances of the devices were characterized by nebulizing 0.5 mL of NaCl 0.9% or 2.0 mL of Ab
130 formulations and laser diffraction. According to the manufacturer's instructions and our observations, the residual
131 volumes were low (<0.1mL) after nebulization, with any devices and formulations. **The concentration of each Ab**
132 **was determined using a NanoDrop 2000 spectrophotometer (Thermo Fisher), at 280 nm, before and after**
133 **nebulization to evaluate any change during the nebulization process.** During each nebulization, the duration was
134 recorded to determine the flow rate. **Each experiment was done in triplicate.**

135

136 *Shaking conditions*

137 Ab solutions (2 mL) were introduced in a 15-mL conical tube (Corning Life Sciences) and agitated with a rotator
138 PTR 60 (Grant bio). The shaking cycle corresponds to successive alternated 360° vertical rotations for 15 seconds

139 at 100 rpm and reciprocal rotations for 45 seconds, for a total of 10 minutes. The rotator was placed in an Ecotron
140 (Infors HT) incubator at 37°C during the entire shaking period. Each experiment was done in triplicate.

141

142 ***Distribution of aerosol droplets by laser diffraction***

143 The volume median diameter (VMD) of aerosol droplets was determined by laser diffraction with a Spraytec
144 (Malvern) equipped with a horizontal inhalation cell (Malvern). The Device 1 was used vertically (normal position)
145 and was connected to the inhalation cell with a T piece. The Device 2 was used horizontally (normal position) and
146 was directly connected to the inhalation cell. The aerosol was aspirated into the inhalation cell with vacuum pump
147 at a flow rate of 15 L/min. The results were expressed as VMD and percentage of droplets with a diameter between
148 1 and 5 µm.

149

150 ***Visual inspection of visible particles***

151 The presence or absence of particles larger than 500 µm was assessed by visual inspection. The samples were
152 placed in a glass vial and illuminated with an MLC-150 cold light source (Motic) on a black background.

153

154 ***Subvisible particles measured by flow-cell microscopy (FCM)***

155 Flow-cell microscopy (FCM) was used to detect particles in the range of 1 µm to 100 µm. All Ab solutions were
156 analyzed before and after nebulization with a particle counting imager Flowcell FC200-IPAC (Occhio) instrument.
157 A volume of 200 µL of each sample was passed through an analysis flow cell and particles were counted and
158 analyzed with the Callisto® software (Occhio). The results were reported as the number of particles per milliliter
159 (particles/mL) and expressed as the concentration of all particles (all particles/mL), particles larger than 2µm (>
160 2µm/mL), particles larger than 10µm (> 10 µm/mL) and particles larger than 25µm (> 25µm/mL).

161

162 ***Submicron particles measured by dynamic light scattering (DLS)***

163 Dynamic light scattering (DLS) was used to analyze particles from 50 nm to 2 µm. The measurements were carried
164 out at 25°C, with a DynaPro NanoStar (Wyatt Technology) instrument using a 659 nm laser wavelength and 90°
165 detection angle. Each sample was introduced in a plastic disposable cuvette (Uvette, Eppendorf) and carried out
166 10 acquisitions of 7 seconds. The data were analyzed with Dynamics 7.1.9 software (Wyatt Technology). Samples
167 with more than 30% of the acquisitions rejected were considered non-exploitable, as recommended by the
168 manufacturer. The acceptance criteria were an autocorrelation curve baseline limited at 1 ± 0.01 and a maximum
169 SOS (Sum-Of-Squares error from the correlation function fit) of 100. The results were displayed as the correlogram
170 curves, the monomer radius (nm), percentage of polydispersity of monomer population (%pd), percentage in
171 intensity (% intensity) and in mass (% mass) of the monomer, which resulted from the regularization analysis. The
172 polydispersity index (PDI) resulting from Cumulant analysis and corresponding to the distribution width divided
173 by the mean, was also reported.

174

175 ***Oligomers measured by size-exclusion chromatography (SEC)***

176 Size exclusion chromatography (SEC) was used to analyze oligomers. The measurements were performed on a
177 series 200 (Perkin Elmer) high performance liquid chromatography (HPLC) system. The samples were filtered
178 through a PES 0.22 µm syringe filter into glass vials with reducers. Samples were maintained at 4°C in the storage

179 system before injection. For each sample, 50 µg of Ab was injected by an autosampler on an Advanced BioSEC
180 300 Å, 2.7 µm, 7.8 x 300 mm (Agilent) column. The elution phase was PBS 1X pH 7.2 with 0.03% (w/v) of NaN₃
181 perfused at a constant flow rate of 1mL/min at a temperature of 25°C. UV detection was performed at 280 nm with
182 diode array detector. The data were recorded and processed with TotalChrom software (Perkin Elmer). Results
183 were expressed as the percentage of high molecular weights species (% HMW).

184

185 ***Biological activity of mAb1***

186 The measurement of activity is based on the measurement of complement-dependent cytotoxicity (CDC) in the
187 presence of mAb1. mAb1 before and after stress (=samples) and mAb1 reference were diluted at different
188 concentrations and incubated with the antigen carrier cells in the wells of a 96-well plate before adding human
189 complement. Living cells remaining in the wells were visualized with a tetrazolium salt and quantified with a
190 plate reader at 450 nm. The absorbance measured by well is inversely proportional to mAb1 cytotoxicity, which
191 allows to determine a dose-response curve for the samples and the reference. The results are presented as a
192 percentage of CDC activity calculated as a ratio of EC₅₀ value of mAb1 samples and mAb1 reference.

193

194 **Results**

195 **Characterization of aerosols when nebulizing Ab formulations for IV**

196 Pulmonary delivery of Ab can be achieved using several types of devices and, in theory, liquid IV Ab formulations
197 may be directly aerosolized using nebulizers. Herein, we used two vibrating mesh-nebulizers, as this type of
198 devices has been shown to maintain better the stability of IgG during nebulization and can achieve large dose
199 delivery with a high pulmonary deposition [9,18,20]. The performances of the devices with saline solutions and
200 Ab formulations were assessed by measuring the VMD of the aerosols and the flow rates. As reported in Table 1,
201 the flow rates of the two devices with the saline solution were less than 0.5 mL/min and the Device 2 was slightly
202 faster. The flow rates for the two devices decreased in the presence of Ab formulations and the drop was more
203 important with Device 1. The reduction depends on the formulations, with the lowest flow rate observed with
204 mAb3 (30 mg/mL, 2.4Cp (20°C)) essentially with device 1.

205 The VMD of Device 1 and Device 2 with saline solutions were 4.1 µm and 3.5 µm and correspond to a respiratory
206 fraction (particles between 1-5 µm) of 64.4 and 71%, respectively. The VMD was not affected by the nebulization
207 of Ab formulations, except for mAb3 for which the VMD was notably smaller with Device 1, thereby increasing
208 the fine particle fraction (Table 1).

209

210 **Characterization of Ab aggregation when nebulizing pharmaceutical Ab formulations**

211 As previously reported, proteins, including IgG, are highly sensitive to nebulization stress, and the main marker
212 of protein instability during nebulization is aggregation [19,22]. The extent of aggregation depends on the protein
213 nature, the nebulizer and the formulation. Here, we investigated the ability of liquid pharmaceutical formulations
214 compatible for IV administration, which were developed to prevent Ab instability during the product lifespan and
215 to certain environmental stress, to protect Ab from degradation during mesh-nebulization. A vigorous shaking
216 method was used as a control. Aggregation was monitored using orthogonal methods allowing to cover the large
217 range of aggregate populations that can be generated.

218 Not surprisingly, aggregation was dependent on Ab properties and the applied stress. All Ab tolerated the vigorous
219 shaking relatively well. No **major** generation of visible, subvisible (Figure 1) or submicron (Table 2) aggregates
220 and oligomers (Table 3) has been detected. After nebulization, no visible particle was observed in the samples for
221 the 3 Abs. However, small subvisible particles (<10 μm) were observed by FCM (Figure 1 and Table 2) in samples
222 after nebulization, mostly with Device 2. Although the number of particles was relatively heterogeneous between
223 nebulization runs, device 2 induced a higher amount of aggregates than device 1 (Figure 1 and Table 2).
224 The DLS profiles (Figure 2) displayed slight changes after nebulization for mAb1 and mAb2 as evidenced by the
225 autocorrelation curves. Additionally, except for mAb3 with Device 1, PDI was increased after nebulization (see
226 Table 2) for the 3 Ab, indicating the presence of submicron aggregates. This hypothesis is further supported by
227 the decrease in intensity of the monomer content. However, the lack of decrease of the monomer content in mass
228 suggest that the submicron particles generated during mesh-nebulization represented a very small quantity of
229 particles. SEC results did not highlight important formation of oligomers, except for the nebulized mAb 3, which
230 had a tendency to produce HMW species with Device 2. mAb 1 was one of the most sensitive IgG to nebulization
231 as exemplified by the amount of subvisible particles, %Pd and PDI index observed after nebulization. Because the
232 instability of protein during nebulization may result in some cases in a loss of activity, we analyzed some features
233 of mAb1 activity after nebulization. As shown in Supplemental Table **S2**, the complement-dependent cytotoxicity
234 of mAb1 was not markedly affected after nebulization.

235

236 **Discussion**

237 Therapeutic Ab, which mainly comprise monoclonal IgG, are one of the most important class of therapeutics and
238 are gaining importance in infectious diseases [4]. Neutralizing the pathogens, inducing anti-infective immune
239 responses and/or preventing excessive inflammation, Ab offer new opportunities for the prevention and treatment
240 of respiratory infections, which still represent unmet medical needs. Several preclinical studies demonstrated the
241 benefit to deliver anti-infective Ab topically to the lungs in viral and bacterial models of respiratory infections
242 [11,23,24] . But the advantage of the inhalation route has not materialized yet in the clinic, thereby emphasizing
243 the challenges to overcome during inhaled Ab development [5]. Among them, the instability of Ab during
244 aerosolization – leading to Ab aggregation- raises both pharmacological and safety issues. The characterization of
245 the best formulation, to ensure the stability of the Ab along its lifespan as a pharmaceutical product, is also a
246 challenge that is faced during intravenous Ab development [25,26]. As a result, formulation scientists select the
247 formulations and explore the Ab stability to various stresses, some of them encountered during aerosolization.
248 Herein, we evaluated the potential use of pharmaceutical formulations, intended for IV delivery, for expanded
249 applications for inhalation.

250 Parenteral protein formulations, including Ab formulations, are being increasingly developed as liquid dosage
251 forms to make them ready to use and to ease use in clinics [14,27]. Thus, numerous IV Ab formulations can be
252 potentially tested in nebulizing systems for inhalation. Previous studies showed that mesh-nebulization was less
253 deleterious on IgG as compared to jet- or ultrasonic-nebulization, most probably because mesh-nebulizers usually
254 display low change in temperature over the nebulization period and no recycling [18,20,28]. However, drug
255 formulations affect mesh-nebulizer performances [28,29]. In particular, ion concentration and increased viscosity
256 were associated with a decrease in droplet size and moderately viscous (>5cP) solutions were not suitable for
257 mesh-nebulization. Herein, the viscosity of Ab formulations was sufficiently low (<5 cP) to enable mesh-

258 nebulization and overall aerosolization was mostly unaffected by formulation characteristics for the two devices.
259 To a lesser extent, mesh-nebulizer performances may also be influenced by surface tension, which depends on
260 formulation, in particular addition of surfactants [29]. For each device, the proportion of respirable droplets were
261 in the same range, which is in agreement with aerodynamic diameter being similar to the ones obtained with saline
262 solutions. Despite a decrease in flow rate, nebulization times remained within an acceptable time range for
263 administration to spontaneously-breathing patients (<15 min for 2mL solution), with the exception of mAb3 with
264 the device 1. Overall, this means that the 3 IV formulations were compatible with aerosol deposition into the
265 respiratory tract.

266 Nebulization-mediated aggregation is a serious issue to consider for inhaled Ab. Indeed, aggregation can result in
267 a loss of Ab activity, as the tertiary structure may be impaired, and can elicit, *in vivo*, antidrug-antibody (ADA)
268 production that may neutralize Ab and lead to side effects, such as hypersensitivity responses and anaphylactic
269 reaction. Accordingly, the presence and levels of Ab aggregates along upstream and downstream processes is
270 highly documented for each product. Aggregation covers a broad range of sizes and the European (Eur. Ph. 703)
271 and United States (USP788) pharmacopeias require to evaluate visible particles and subvisible particles over 10
272 and 25 μm for drug product release [30]. In addition, the regulatory agencies recommend to monitor smaller sized
273 aggregates, including subvisible particles (2-10 μm) and submicronic particles (0.1-2 μm), for full protein product
274 characterization as they may pose a clinical risk [31]. In this study, pharmaceutical Ab formulations subjected to
275 mesh-nebulization resulted in a slight to moderate increase of subvisible particles, mostly those <10 μm . The
276 aggregation profile, as characterized by orthogonal methods, was dependent on the mAb and the mesh-nebulizer.
277 The difference of stability observed with the two mesh-nebulizers may be attributable to heating, shear and
278 mechanical stress inherent to each device or the aerosol size, increasing the air-liquid interface [18,19]. Although
279 IV Ab development takes into account Ab stability to environment stress, such as temperature rise and shearing,
280 pharmaceutical formulations did not seem appropriate for inhalation. Combination of shear stress and local thermal
281 stress appears unique for nebulizers and is likely not enough accurately mimicked by the shaking and thermal
282 stresses as applied for IV formulation development. Our findings are in agreement with those obtained for other
283 parenteral protein formulations [32].

284 Aggregation may be associated to a loss of activity. Thus, one may question the impact of the aggregates produced
285 during mesh-nebulization on Ab activity. As for mAb1, its biological activity was unaffected by mesh-nebulization
286 (see supplemental Table S1). However, it would be difficult to extrapolate this finding to other Ab, since
287 nebulization-mediated aggregation was inconsistently associated with altered Ab activity [21]. Aggregation is also
288 associated to Ab-related immunogenicity and immunogenicity depends for a part on the route of administration.
289 To the best of our knowledge, the impact of aggregates generated during mesh-nebulization and after inhalation
290 on immune responses has not been investigated yet. But, small-sized subvisible particles (2-10 μm), which
291 correspond to the aggregates mostly produced during mesh-nebulization, have been shown to enhance immune
292 response and are expected to be the most immunogenic [33,34].

293 It is noteworthy that a vigorous mechanical shaking at elevated temperature was unable to reproduce the combined
294 shear thermal stresses applied in mesh-nebulizer. Overall, the 3 Abs displayed remarkable stability towards strong
295 mechanical shaking. Our results do not match those of Hertel et al. (2014), who defined a shaking method as a
296 surrogate of nebulization stress for protein therapeutics, using one protein nebulized with one device as a study
297 model [32]. In addition to the slight differences between the methods of “shaking at elevated temperature”, the

298 discrepancy may be attributable to the protein nature and the device. As for us, vigorous shaking at elevated
299 temperature may mimic in some but not all cases, mesh-nebulization. This may be explained by the difficulty to
300 reproduce some nebulization stress by shaking, in particular the huge air-liquid interface generated by pumping
301 the liquid through the mesh and, by definition, in the aerosol droplets. Moreover, local and transient temperature
302 rise in the reservoir of the nebulizer may contribute to additional aggregation. From a formulation scientist's
303 perspective, it means that the vigorous shaking applied in the present study is not suitable to accelerate inhaled Ab
304 development and the study of the stress induced by the device intended for human use has to be performed early
305 in the development process.

306 Parenteral Ab formulations and particularly intravenous injectable dosage forms require pH and osmolality
307 characteristics basically compatible for inhalation as the lungs tolerate inhaled drug products with osmolality
308 ranging 150–549 mOsm/kg - even if isotonicity has been recommended- and pH ranging 3.5 to 8.0 [35]. Beyond
309 the pH and osmolality, the excipients (nature and dose) in the IV Ab formulations may not be adapted to inhalation
310 and if not used in inhaled drug products they would require toxicity investigations by the inhalation route.

311 Overall, our findings indicate that Ab formulations developed for IV delivery may not easily be repurposed for
312 inhalation delivery and point to the requirement of a specific formulation development for inhaled Ab. Formulation
313 scientists may select carefully the dose and excipients to be added in the formulation to stabilize Ab during mesh-
314 nebulization, taking into account the paucity of toxicity data on inhaled excipients and their potential impact on
315 formulation properties, and thereby device performances.

316

317 **Acknowledgements**

318 This work was supported by the French National Research Agency as part of the “Investissements d'Avenir”
319 program (LabEx MAbImprove, ANR-10-LABX-53-01) and SANOFI. AM was funded by a CIFRE thesis
320 partnership between the CEPR-Inserm U1100 and Sanofi.

321 We would like to thank Ronan Crepin (Sanofi) for his technical assistance.

322

323 **References**

- 324 1. Why Amnesty opposes the death penalty without exception [Internet]. [cited 2020 Sep 16]. Available from:
325 <https://www.amnesty.org/en/what-we-do/death-penalty/>
- 326 2. Ritchie H, Roser M. Causes of Death. Our World in Data [Internet]. 2018 [cited 2020 Sep 16]; Available
327 from: <https://ourworldindata.org/causes-of-death>
- 328 3. COVID-19 Map [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2020 Sep 21]. Available from:
329 <https://coronavirus.jhu.edu/map.html>
- 330 4. Sécher T, Guilleminault L, Reckamp K, Amanam I, Plantier L, Heuzé-Vourc'h N. Therapeutic antibodies: A
331 new era in the treatment of respiratory diseases? *Pharmacol Ther.* 2018;189:149–72.
- 332 5. Sécher T, Mayor A, Heuzé-Vourc'h N. Inhalation of Immuno-Therapeutics/-Prophylactics to Fight
333 Respiratory Tract Infections: An Appropriate Drug at the Right Place! *Front Immunol.* 2019;10:2760.
- 334 6. COVID-19 Antibody Therapeutics Tracker – Chinese Antibody Society [Internet]. [cited 2020 Sep 16].
335 Available from: <https://chineseantibody.org/covid-19-track/>
- 336 7. Reports [Internet]. Global Initiative for Asthma - GINA. [cited 2020 Sep 16]. Available from:
337 <https://ginasthma.org/reports/>

- 338 8. Gold Reports for Personal Use [Internet]. Global Initiative for Chronic Obstructive Lung Disease - GOLD.
339 [cited 2020 Sep 16]. Available from: <https://goldcopd.org/gold-reports/>
- 340 9. Bodier-Montagutelli E, Mayor A, Vecellio L, Respaud R, Heuzé-Vourc'h N. Designing inhaled protein
341 therapeutics for topical lung delivery: what are the next steps? *Expert Opin Drug Deliv.* 2018;15:729–36.
- 342 10. COVID-19 [Internet]. Synairgen. [cited 2020 Sep 16]. Available from: <https://www.synairgen.com/covid-19/>
- 343 11. Sécher T, Dalonneau E, Ferreira M, Parent C, Azzopardi N, Paintaud G, et al. In a murine model of acute
344 lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral
345 administration. *J Control Release.* 2019;303:24–33.
- 346 12. Guillon A, Sécher T, Dailey LA, Vecellio L, de Monte M, Si-Tahar M, et al. Insights on animal models to
347 investigate inhalation therapy: Relevance for biotherapeutics. *International Journal of Pharmaceutics.*
348 2018;536:116–26.
- 349 13. Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, et al. The Airways, a Novel
350 Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. *Pharm Res.* 2011;28:2147–56.
- 351 14. Falconer RJ. Advances in liquid formulations of parenteral therapeutic proteins. *Biotechnology Advances*
352 [Internet]. 2019 [cited 2020 Jan 25];37. Available from:
353 <http://www.sciencedirect.com/science/article/pii/S0734975019301028>
- 354 15. Anonymous. ICH Q1A (R2) Stability testing of new drug substances and products [Internet]. European
355 Medicines Agency. 2018 [cited 2020 Sep 21]. Available from: [https://www.ema.europa.eu/en/ich-q1a-r2-](https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products)
356 [stability-testing-new-drug-substances-drug-products](https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products)
- 357 16. Anonymous. ICH Q6B Specifications: test procedures and acceptance criteria for biotechnological/biological
358 products [Internet]. European Medicines Agency. 2018 [cited 2020 Sep 21]. Available from:
359 [https://www.ema.europa.eu/en/ich-q6b-specifications-test-procedures-acceptance-criteria-](https://www.ema.europa.eu/en/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnologicalbiological-products)
360 [biotechnologicalbiological-products](https://www.ema.europa.eu/en/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnologicalbiological-products)
- 361 17. Anonymous. ICH Q8 (R2) Pharmaceutical development [Internet]. European Medicines Agency. 2018 [cited
362 2020 Sep 21]. Available from: <https://www.ema.europa.eu/en/ich-q8-r2-pharmaceutical-development>
- 363 18. Hertel SP, Winter G, Friess W. Protein stability in pulmonary drug delivery via nebulization. *Advanced Drug*
364 *Delivery Reviews.* 2015;93:79–94.
- 365 19. Respaud R, Vecellio L, Diot P, Heuzé-Vourc'h N. Nebulization as a delivery method for mAbs in respiratory
366 diseases. *Expert Opin Drug Deliv.* 2015;12:1027–39.
- 367 20. Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, et al. Aerodynamical,
368 Immunological and Pharmacological Properties of the Anticancer Antibody Cetuximab Following Nebulization.
369 *Pharm Res.* 2008;25:1318–26.
- 370 21. Bodier-Montagutelli E, Respaud R, Perret G, Baptista L, Duquenne P, Heuzé-Vourc'h N, et al. Protein
371 stability during nebulization: Mind the collection step! *European Journal of Pharmaceutics and*
372 *Biopharmaceutics.* 2020;152:23–34.
- 373 22. Depreter F, Pilcer G, Amighi K. Inhaled proteins: Challenges and perspectives. *International Journal of*
374 *Pharmaceutics.* 2013;447:251–80.
- 375 23. Larios Mora A, Detalle L, Gallup JM, Van Geelen A, Stohr T, Duprez L, et al. Delivery of ALX-0171 by
376 inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. *MAbs.* 2018;10:778–95.
- 377 24. Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P. Direct Administration in the Respiratory Tract
378 Improves Efficacy of Broadly Neutralizing Anti-Influenza Virus Monoclonal Antibodies. *Antimicrob Agents*
379 *Chemother.* 2015;59:4162–72.

- 380 25. Brovč EV, Mravljak J, Šink R, Pajk S. Rational design to biologics development: The polysorbates point of
381 view. *International Journal of Pharmaceutics*. 2020;581:119285.
- 382 26. Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V. Physicochemical Stability of Monoclonal
383 Antibodies: A Review. *Journal of Pharmaceutical Sciences* [Internet]. 2019 [cited 2019 Dec 21]; Available from:
384 <http://www.sciencedirect.com/science/article/pii/S0022354919305064>
- 385 27. Gervasi V, Dall Agnol R, Cullen S, McCoy T, Vucen S, Crean A. Parenteral protein formulations: An
386 overview of approved products within the European Union. *European Journal of Pharmaceutics and*
387 *Biopharmaceutics*. 2018;131:8–24.
- 388 28. Carvalho TC, McConville JT. The function and performance of aqueous aerosol devices for inhalation
389 therapy. *J Pharm Pharmacol*. 2016;68:556–78.
- 390 29. Ghazanfari T, Elhissi AMA, Ding Z, Taylor KMG. The influence of fluid physicochemical properties on
391 vibrating-mesh nebulization. *International Journal of Pharmaceutics*. 2007;339:103–11.
- 392 30. Zölls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, et al. Particles in Therapeutic
393 Protein Formulations, Part 1: Overview of Analytical Methods. *Journal of Pharmaceutical Sciences*.
394 2012;101:914–35.
- 395 31. FDA Guidance for Industry - Immunogenicity Assessment for Therapeutic Protein Products. 2014.
- 396 32. Hertel S, Pohl T, Friess W, Winter G. Prediction of protein degradation during vibrating mesh nebulization
397 via a high throughput screening method. *Eur J Pharm Biopharm*. 2014;87:386–94.
- 398 33. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Russell Middaugh C, Winter G, et al. Overlooking
399 Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. *Journal of*
400 *Pharmaceutical Sciences*. 2009;98:1201–5.
- 401 34. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, et al. Pathogen recognition and
402 development of particulate vaccines: does size matter? *Methods*. 2006;40:1–9.
- 403 35. Beasley R, Rafferty P, Holgate ST. Adverse reactions to the non-drug constituents of nebuliser solutions.
404 *British Journal of Clinical Pharmacology*. 1988;25:283–7.
- 405